Nuvation Bio Inc
NUVB2.272USD
+0.042+1.88%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
772.08MCap. mercado
PérdidaP/E TTM
Más Datos de Nuvation Bio Inc Compañía
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Información de la empresa
Símbolo de cotizaciónNUVB
Nombre de la empresaNuvation Bio Inc
Fecha de salida a bolsaJul 01, 2020
Director ejecutivoDr. David T. Hung, M.D.
Número de empleados220
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 01
Dirección357 Tehama Street, Floor 3
CiudadSAN FRANCISCO
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal94103
Teléfono14157543517
Sitio Webhttps://www.nuvationbio.com/
Símbolo de cotizaciónNUVB
Fecha de salida a bolsaJul 01, 2020
Director ejecutivoDr. David T. Hung, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
7.30K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
Accionistas
Accionistas
Proporción
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
30.97%
Individual Investor
19.30%
Hedge Fund
12.40%
Investment Advisor/Hedge Fund
9.48%
Venture Capital
8.02%
Research Firm
1.03%
Bank and Trust
0.20%
Pension Fund
0.17%
Private Equity
0.01%
Other
18.42%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
340
277.65M
81.60%
-29.03M
2025Q1
346
276.31M
81.30%
-31.14M
2024Q4
336
290.52M
86.58%
+4.56M
2024Q3
324
278.55M
83.07%
+36.83M
2024Q2
323
221.78M
89.68%
-2.09M
2024Q1
305
194.38M
89.06%
-41.04M
2023Q4
290
194.02M
89.00%
-35.90M
2023Q3
285
196.95M
90.37%
-25.21M
2023Q2
286
199.03M
91.34%
-20.86M
2023Q1
290
197.27M
90.57%
-23.29M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Hung (David T)
60.28M
17.72%
+500.00K
+0.84%
Jun 16, 2025
Fidelity Management & Research Company LLC
50.03M
14.7%
+5.31M
+11.88%
Mar 31, 2025
Decheng Capital LLC
25.95M
7.63%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
15.87M
4.66%
-60.61K
-0.38%
Mar 31, 2025
The Vanguard Group, Inc.
15.34M
4.51%
-334.75K
-2.14%
Mar 31, 2025
Omega Fund Management, LLC
13.07M
3.84%
--
--
Mar 31, 2025
Laurion Capital Management LP
9.87M
2.9%
+3.38M
+52.06%
Mar 31, 2025
Octagon Capital Advisors LP
7.90M
2.32%
-1.30M
-14.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.13M
1.51%
+179.41K
+3.62%
Mar 31, 2025
State Street Global Advisors (US)
4.86M
1.43%
+256.02K
+5.57%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
SPDR S&P Pharmaceuticals ETF
0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.63%
ALPS Medical Breakthroughs ETF
0.45%
iShares U.S. Pharmaceuticals ETF
0.25%
iShares Micro-Cap ETF
0.11%
iShares Health Innovation Active ETF
0.08%
Avantis US Small Cap Equity ETF
0.06%
iShares Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.97%
SPDR S&P Pharmaceuticals ETF
Proporción0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.63%
ALPS Medical Breakthroughs ETF
Proporción0.45%
iShares U.S. Pharmaceuticals ETF
Proporción0.25%
iShares Micro-Cap ETF
Proporción0.11%
iShares Health Innovation Active ETF
Proporción0.08%
Avantis US Small Cap Equity ETF
Proporción0.06%
iShares Biotechnology ETF
Proporción0.05%
Fidelity Enhanced Small Cap ETF
Proporción0.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
